التفاصيل البيبلوغرافية
| العنوان: |
Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia. |
| المؤلفون: |
Liedtke, Michaela1 mliedtke@stanford.edu, Dunn, Tamara1, Dinner, Shira1, Coutré, Steven E.1, Berube, Caroline1, Gotlib, Jason1, Patel, Samit2, Medeiros, Bruno1 |
| المصدر: |
Leukemia Research. Dec2014, Vol. 38 Issue 12, p1441-1445. 5p. |
| مصطلحات موضوعية: |
*LYMPHOBLASTIC leukemia treatment, *SALVAGE therapy, *MITOXANTRONE, *ETOPOSIDE, *CYTARABINE, *DISEASE relapse, *RETROSPECTIVE studies, *THERAPEUTICS |
| مستخلص: |
The survival of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) is poor. We performed a retrospective analysis of 40 patients treated with five days of mitoxantrone 8 mg/m 2 /day, etoposide 100 mg/m 2 /day, and cytarabine 1000 mg/m 2 /day (MEC). The complete remission rate was 30% and median remission duration was 11.2 months. Median overall survival was 6.5 months. In univariate analysis, patients in first relapse had improved overall survival compared to ≥second relapse ( p = 0.02). Thirty-day mortality rate was 7.5%. In relapsed or refractory ALL, MEC demonstrated moderate activity, but did not improve survival compared to published salvage chemotherapy regimens. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
